For Immediate Release
Chicago, IL – January 10, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cutera Inc (CUTR - Free Report) , IRIDEX Corporation (IRIX - Free Report) , Cynosure Inc. (CYNO - Free Report) , Palomar Medical Technologies and Syneron Medical Ltd. (ELOS - Free Report) .
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: https://at.zacks.com/?id=5513
Here are highlights from Monday’s Analyst Blog:
Cutera Buys IRIDEX’s Aesthetic Biz
Medical devices maker Cutera Inc (CUTR - Free Report) recently cut an asset purchase deal with California-based laser systems and delivery devices maker IRIDEX Corporation (IRIX - Free Report) . Under the deal, Cutera has agreed to acquire specific aesthetic laser assets of IRIDEX for roughly $5.1 million.
The transaction, which has been cleared by the Boards of both companies, is expected to complete in early 2012. Cutera expects to finance the deal using its available cash resources.
Both Cutera and IRIDEX currently serves the roughly $1 billion worldwide aesthetic market. The acquisition of IRIDEX’s aesthetic assets will bolster Cutera’s foothold in the vascular aesthetic market.
The acquisition adds IRIDEX’s portable VariLite dual wavelength system to Cutera’s vascular laser product range (includes the Excel V laser), enabling the company to offer physicians a comprehensive suite of solutions for treating a broad spectrum of vascular aesthetic indications.
Under the pact, IRIDEX has agreed to provide Cutera with transitional product and service support. The divestiture of its aesthetic laser assets to Cutera will allow the company to refocus on the core ophthalmology opportunity, which is critical for its future growth.
Cutera develops and markets laser aesthetics systems for physicians and qualified practitioners globally and offers its products under three platforms, such as, Solera, Xeo and CoolGlide. The company markets its products through a direct sales force and distributors. Cutera competes with Cynosure Inc. (CYNO - Free Report) , Palomar Medical Technologies and Syneron Medical Ltd. (ELOS - Free Report) among others.
Cutera recently announced fourth-quarter 2011 preliminary revenues of roughly $18 million. The company noted that it has maintained double-digit sales growth for the third consecutive quarter. Cutera expects to unveil full results for the quarter on February 13.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: https://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: https://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at https://at.zacks.com/?id=5518.
Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339